MARKET

GRFS

GRFS

Grifols S A
NASDAQ
7.82
+0.04
+0.51%
Opening 10:54 07/26 EDT
OPEN
8.05
PREV CLOSE
7.78
HIGH
8.07
LOW
7.81
VOLUME
377.66K
TURNOVER
0
52 WEEK HIGH
12.15
52 WEEK LOW
5.30
MARKET CAP
5.38B
P/E (TTM)
25.77
1D
5D
1M
3M
1Y
5Y
1D
EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever
Analysts revise their ratings and price targets on several European companies. Greencore, UCB, and Unilever revise their targets. Lonza Group, Air France-KLM and Anglo American all raise their targets for the day. Air France cuts its target price for Air France.
Reuters · 18h ago
Weekly Report: what happened at GRFS last week (0715-0719)?
Weekly Report · 4d ago
Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +
Home Stock Ideas Quick Picks & Lists Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals. We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. The 'Undercovered' Dozen series highlights undercovered stocks on our platform. Rubrik, Inc. Is a compelling buy post-IPO. Polestar Automotive Holding is a sell. HubSpot faces volatility post-Google acquisition plans.
Seeking Alpha · 07/19 18:15
Grifols: Going Private? Brookfield On The Scene
Spanish pharmaceutical company Grifols faces challenges with high debt levels and difficulty in refinancing. Brookfield Asset Management is in talks with majority shareholders to potentially privatize the company. Moody's downgraded the corporate rating of the company to junk status. The company's cash flow recovery is not expected to be good in Q2.
Seeking Alpha · 07/16 10:59
Grifols: Stay On The Sidelines
Seeking Alpha · 07/16 09:00
Weekly Report: what happened at GRFS last week (0708-0712)?
Weekly Report · 07/15 09:23
Grifols board to back a potential go-private deal
Healthcare Grifols board to back a potential go-private deal involving its founding family and asset manager, Brookfield Fund. Shares of the Spanish plasma therapeutics company surged this week after a preliminary offer from the Grifol's family and Brookfield was announced. The company's board of directors unanimously adopted measures to facilitate the deal.
Seeking Alpha · 07/12 17:35
Grifols Board Votes To Grant Brookfield Access To Information For Potential Takeover Bid; Establishes Independent Committee To Monitor Transaction Progress And Present Proposals To Board
Benzinga · 07/12 16:54
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.

Webull offers Grifols SA - ADR stock information, including NASDAQ: GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.